Risk of serious infection

Makoto Naganuma

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Anti-TNF therapy is effective for inducing and maintaining remission in both pediatric Crohn's disease and ulcerative colitis patients; however, adverse effects, such as serious infection and lymphoma, are of concern. A recent study has indicated that anti-TNFa therapy in patients aged ≥ 50 years is associated with significantly increased rates of serious infections; therefore, physicians should pay careful attention to detect the development of infections in elderly patients treated with this therapy. Patients with inflammatory bowel disease (IBD) should be considered for the five following vaccines: the varicella zoster, human papillomavirus, influenza, hepatitis B, and pneumococcal vaccines. Because IBD patients often fail to recognize whether they have previously had a vaccinepreventive illness, such as varicella zoster virus infection, antibodies for varicella zoster virus should be measured as early as possible after diagnosis of IBD, and vaccination might be considered for patients who do not have antibodies before anti-TNFa agents are used.

Original languageEnglish
Title of host publicationAnti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
PublisherS. Karger AG
Pages147-151
Number of pages5
ISBN (Print)9783318054743, 9783318054736
DOIs
Publication statusPublished - 2015 Jul 9

ASJC Scopus subject areas

  • Chemistry(all)

Fingerprint Dive into the research topics of 'Risk of serious infection'. Together they form a unique fingerprint.

Cite this